Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
20/06/2024 | 22:30 | Business Wire | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:GERN | Geron Corp |
12/06/2024 | 22:05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GERN | Geron Corp |
10/06/2024 | 23:53 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GERN | Geron Corp |
07/06/2024 | 22:03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:GERN | Geron Corp |
07/06/2024 | 03:58 | Business Wire | Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia | NASDAQ:GERN | Geron Corp |
02/05/2024 | 13:00 | Business Wire | Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights | NASDAQ:GERN | Geron Corp |
25/04/2024 | 22:30 | Business Wire | Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 | NASDAQ:GERN | Geron Corp |
03/04/2024 | 22:30 | Business Wire | Geron to Participate at Upcoming Investor Conferences in April | NASDAQ:GERN | Geron Corp |
19/03/2024 | 14:07 | Business Wire | Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | NASDAQ:GERN | Geron Corp |
14/03/2024 | 20:54 | Business Wire | Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | NASDAQ:GERN | Geron Corp |
28/02/2024 | 13:05 | Business Wire | Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:GERN | Geron Corp |
14/02/2024 | 23:01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GERN | Geron Corp |
14/02/2024 | 22:30 | Business Wire | Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 | NASDAQ:GERN | Geron Corp |
12/01/2024 | 14:30 | Business Wire | Geron to Participate in the B. Riley Securities Virtual Oncology Conference | NASDAQ:GERN | Geron Corp |
11/12/2023 | 22:15 | Business Wire | Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS | NASDAQ:GERN | Geron Corp |
06/12/2023 | 14:00 | Business Wire | Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis | NASDAQ:GERN | Geron Corp |
04/12/2023 | 11:00 | Business Wire | Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS | NASDAQ:GERN | Geron Corp |
28/11/2023 | 22:08 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:GERN | Geron Corp |
28/11/2023 | 14:00 | Business Wire | Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors | NASDAQ:GERN | Geron Corp |
07/11/2023 | 22:30 | Business Wire | Geron to Participate at Upcoming Investor Conferences in November | NASDAQ:GERN | Geron Corp |
02/11/2023 | 22:01 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:GERN | Geron Corp |
02/11/2023 | 14:00 | Business Wire | Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS | NASDAQ:GERN | Geron Corp |
02/11/2023 | 13:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:GERN | Geron Corp |
02/11/2023 | 13:00 | Business Wire | Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results | NASDAQ:GERN | Geron Corp |
26/10/2023 | 22:30 | Business Wire | Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023 | NASDAQ:GERN | Geron Corp |
29/09/2023 | 14:00 | Business Wire | Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS | NASDAQ:GERN | Geron Corp |
28/09/2023 | 01:32 | Edgar (US Regulatory) | Form 3/A - Initial statement of beneficial ownership of securities: [Amend] | NASDAQ:GERN | Geron Corp |
12/09/2023 | 15:23 | IH Market News | Keep An Eye Out: Pre-Market Movers And Recommendations | NASDAQ:GERN | Geron Corp |
11/09/2023 | 22:30 | Business Wire | Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer | NASDAQ:GERN | Geron Corp |
07/09/2023 | 14:00 | Business Wire | Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting | NASDAQ:GERN | Geron Corp |